Immunomedics Inc. will file in 1992 for European marketingapproval of its ImmuRaid-CEA, the company said.

ImmuRaid is an in vivo imaging product to diagnose and detectcolorectal cancer. It consists of a monoclonal antibody fragmentlinked with technetium-99.

The Warren, N.J., company is negotiating for a Europeanmarketing partner, spokesman Joe Schepers said. In January,Immunomedics began talks with Boehringer Ingelheim GmbHaimed at a European marketing agreement, but thosediscussions ended without an agreement.

Immunomedics filed in April for U.S. marketing approval ofImmuRaid. Its stock (NADSAQ:IMMU) closed down 13 cents at$10.75 on Monday.

(c) 1997 American Health Consultants. All rights reserved.